Finance

Lists
ACRS:NASDAQ
Aclaris Therapeutics Inc
US$3.68
-1.60%
(-0.060) 1D
US$3.82
+3.80% (+0.14)
After hours
Closed: ኖቬም 4, 4:00:01 ከሰዓት ጂ ኤም ቲ-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACRS...
Open
US$3.81
High
US$3.88
Low
US$3.63
Mkt. cap
543.20 ሚ
Avg. vol.
3.51 ሚ
Volume
317.00
52-wk high
US$6.60
52-wk low
US$2.10
EPS
-US$0.59
Beta
0.96
Shares outstanding
147.20 ሚ
No. of employees
71
Open
US$3.81
High
US$3.88
Low
US$3.63
Mkt. cap
543.20 ሚ
Avg. vol.
3.51 ሚ
Volume
317.00
52-wk high
US$6.60
52-wk low
US$2.10
EPS
-US$0.59
Beta
0.96
Shares outstanding
147.20 ሚ
No. of employees
71
News stories
From web sources and news partners
About Aclaris Therapeutics Inc
CEO-
Employees71
Founded2012
Headquarters-
SectorPharmaceutical industry
Industry-
Analyst ratings
Based on 7 analysts giving stock ratings to ACRS in the past 3 months
Strong buy
Buy
7
Hold
0
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for ACRS in the last 3 months.
Highest
Current US$3.68
US$16.00 (+334.78%)
Average
US$12.00 (+226.09%)
Lowest
US$9.00 (+144.57%)
Analyst
Recommendation
Action
Price target
Projected
Date
Edward Nash
Canaccord Genuity
Buy
Reiterated
US$13.00
+253.3%
10/30/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
US$12.00
+226.1%
10/28/2026
Adam Vogel
Craig-Hallum
Buy
Maintained
US$9.00
+144.6%
10/28/2026
Unknown Analyst
Oppenheimer
Buy
Reiterated
US$10.00
+171.7%
10/28/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$16.00
+334.8%
10/28/2026
Biren Amin
Piper Sandler
Buy
Maintained
US$11.00
+198.9%
10/19/2026
Kate Dellorusso
LifeSci Capital
Buy
Maintained
US$13.00
+253.3%
10/01/2026
Martin Fan
Wedbush
Buy
Maintained
US$10.00
+171.7%
05/08/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
US$10.00
+171.7%
05/08/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
US$4.00
+8.7%
05/08/2026
Unknown Analyst
Goldman Sachs
Buy
Maintained
US$10.00
+171.7%
04/16/2026
Next call በ8 ቀናት ውስጥ
ዓርብ፣ ኖቬም 13, 7:30 ከሰዓት
Fiscal period
Q3 2026
- / -US$0.16
Revenue / Est. (USD)
- / 1.23 ሚ
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
ሴፕቴ 2025
ዲሴም 2025
ማርች 2026
ጁን 2026
Revenue
3.30 ሚ
1.30 ሚ
2.00 ሚ
1.63 ሚ
Cost of goods sold
15.48 ሚ
18.05 ሚ
17.44 ሚ
19.52 ሚ
Cost of revenue
15.48 ሚ
18.05 ሚ
17.44 ሚ
19.52 ሚ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.87 ሚ
5.58 ሚ
6.74 ሚ
6.05 ሚ
Operating expense
4.87 ሚ
5.58 ሚ
6.74 ሚ
6.05 ሚ
Total operating expenses
20.35 ሚ
23.63 ሚ
24.19 ሚ
25.57 ሚ
Operating income
-17.05 ሚ
-22.33 ሚ
-22.19 ሚ
-23.94 ሚ
Other non operating income
716.00 ሺ
1.30 ሚ
854.00 ሺ
972.00 ሺ
EBT including unusual items
-14.61 ሚ
-19.80 ሚ
-19.82 ሚ
-21.50 ሚ
EBT excluding unusual items
-14.51 ሚ
-19.40 ሚ
-19.82 ሚ
-21.20 ሚ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14.61 ሚ
-19.80 ሚ
-19.82 ሚ
-21.50 ሚ
Net profit margin
-442.98%
-1,528.57%
-993.19%
-1,320.13%
Earnings per share
-0.12
-0.16
-0.15
-0.15
Interest and investment income
1.82 ሚ
1.63 ሚ
1.51 ሚ
1.76 ሚ
Interest expense
-
-
-
-
Net interest expenses
1.82 ሚ
1.63 ሚ
1.51 ሚ
1.76 ሚ
Depreciation and amortization charges
-
-
-
-
EBITDA
-17.04 ሚ
-22.32 ሚ
-22.19 ሚ
-23.94 ሚ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google መተግበሪያዎች